Effects of interferon-alpha treatment on neutrophil oxidative metabolism, lymphocyte proliferation and monocyte HLA class I antigen expression in patients with chronic hepatitis C

Immunopharmacol Immunotoxicol. 1996 Nov;18(4):529-48. doi: 10.3109/08923979609052752.

Abstract

Polymorphonuclear cell (PMN) oxidative metabolism, lymphocyte polyclonal proliferation and monocyte HLA class I antigen expression were evaluated at different intervals of time in patients with chronic hepatitis C (CH-C) subjected to a 6 month interferon alpha (IFN-alpha) treatment and divided into Responder ('R') and Nonresponder ('NR') subsets according to clinical outcome. Before therapy, all subjects exhibited multiple immune alterations even if to a different extent between 'R' and 'NR' subsets: an elevated superoxide anion (O2-) generation by suspended PMN, a failure to further increase neutrophil oxidative responsiveness under adherence conditions, an augmented phytohaemagglutin-induced lymphocyte proliferative capacity and an enhanced HLA class I antigen expression on CD14+ cells. IFN-alpha administration gave rise to a modulation of oxidative response in 'R' group only, since these individuals displayed an O2- release by suspended and adherent PMN which fell within normal values. At the same time, a decrease of lymphocyte proliferation occurred in both groups of patients during IFN-alpha therapy, even if it reached statistical significance in 'R' group only. Finally, a more marked difference between 'R' and 'NR' individuals was noted in terms of HLA class I antigen induction on CD14+ cells at the end of therapy, as a consequence of a reduced expression of these structures in 'NR' subjects. Altogether, these findings suggest the occurrence of a strict relationship between immunoresponsiveness and IFN-alpha induced therapeutical effects in CH-C patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Chronic Disease
  • Female
  • HLA Antigens / biosynthesis*
  • HLA Antigens / drug effects
  • Hepatitis C / drug therapy*
  • Histocompatibility Antigens Class I / biosynthesis*
  • Histocompatibility Antigens Class I / drug effects
  • Humans
  • Interferon-alpha / therapeutic use*
  • Lymphocyte Activation / drug effects*
  • Male
  • Middle Aged
  • Monocytes / drug effects*
  • Monocytes / metabolism*
  • Neutrophils / drug effects*
  • Oxidation-Reduction

Substances

  • HLA Antigens
  • Histocompatibility Antigens Class I
  • Interferon-alpha